Cargando…
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945710/ https://www.ncbi.nlm.nih.gov/pubmed/29600394 http://dx.doi.org/10.1007/s40257-018-0353-x |
| _version_ | 1783322040966578176 |
|---|---|
| author | Blauvelt, Andrew Papp, Kim A. Griffiths, Christopher E. M. Puig, Luis Weisman, Jamie Dutronc, Yves Kerr, Lisa Farmer Ilo, Dapo Mallbris, Lotus Augustin, Matthias |
| author_facet | Blauvelt, Andrew Papp, Kim A. Griffiths, Christopher E. M. Puig, Luis Weisman, Jamie Dutronc, Yves Kerr, Lisa Farmer Ilo, Dapo Mallbris, Lotus Augustin, Matthias |
| author_sort | Blauvelt, Andrew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5945710 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59457102018-05-15 Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) Blauvelt, Andrew Papp, Kim A. Griffiths, Christopher E. M. Puig, Luis Weisman, Jamie Dutronc, Yves Kerr, Lisa Farmer Ilo, Dapo Mallbris, Lotus Augustin, Matthias Am J Clin Dermatol Correction Springer International Publishing 2018-03-29 2018 /pmc/articles/PMC5945710/ /pubmed/29600394 http://dx.doi.org/10.1007/s40257-018-0353-x Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Correction Blauvelt, Andrew Papp, Kim A. Griffiths, Christopher E. M. Puig, Luis Weisman, Jamie Dutronc, Yves Kerr, Lisa Farmer Ilo, Dapo Mallbris, Lotus Augustin, Matthias Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) |
| title | Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) |
| title_full | Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) |
| title_fullStr | Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) |
| title_full_unstemmed | Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) |
| title_short | Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) |
| title_sort | correction to: efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase iii randomized clinical trials in moderate-to-severe plaque psoriasis (uncover-2 and -3) |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945710/ https://www.ncbi.nlm.nih.gov/pubmed/29600394 http://dx.doi.org/10.1007/s40257-018-0353-x |
| work_keys_str_mv | AT blauveltandrew correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 AT pappkima correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 AT griffithschristopherem correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 AT puigluis correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 AT weismanjamie correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 AT dutroncyves correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 AT kerrlisafarmer correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 AT ilodapo correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 AT mallbrislotus correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 AT augustinmatthias correctiontoefficacyandsafetyofswitchingtoixekizumabinetanerceptnonrespondersasubanalysisfromtwophaseiiirandomizedclinicaltrialsinmoderatetosevereplaquepsoriasisuncover2and3 |